Participants with dry eye disease, oil gland disruption and blepharitis will receive 3 treatments with these LLLT, each separted by 1 week apart, and followed up to 1 month after the final treatment session. Participants will be randomised to either of 3 groups: Red light only group, Red + Blue light group, or a sham treatment group. conditions: Dry Eye Syndromes conditions: Meibomian Gland Dysfunction conditions: Blepharitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Each participant is randomised to either of 3 groups: Red light only group, red plus blue light group, or sham treatment group. primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 36 type: ESTIMATED name: Red LLLT name: Blue LLLT name: Sham Red LLLT name: Sham Blue LLLT measure: Change from Baseline in Non-invasive Tear Break Up Time to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Visual Acuity to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Blink Rate to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Tear Meniscus Height to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Lipid Layer Pattern Grading to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Bulbar Conjunctival Hyperaemia to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Limbal Conjunctival Hyperaemia to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Bacterial Colony to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Blood Flow to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Saponification Grading to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Demodex Presence to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Number of Blocked or Capped Meibomian Glands to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Lid Margin Telangiectasia Grading to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Meibum Expressibility to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Meibum Quality to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Fluorescein Corneal Staining to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Bulbar Conjunctival Staining to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Lissamine Green Lid Wiper Epitheliopathy to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Meibography Meiboscore to the Final Follow-up 1 Month After Final Treatment Session measure: Change from Baseline in Total Corneal Nerve Length to the Final Follow-up 1 Month After Final Treatment Session sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Aston Dry Eye Clinic city: Birmingham state: West Midlands zip: B4 7ET country: United Kingdom name: Jeremy Chung Bo Chiang, PhD role: CONTACT phone: +441212043934 phoneExt: 3934 email: j.chiang@aston.ac.uk lat: 52.48142 lon: -1.89983 hasResults: False